Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and onset of action of azelastine nasal spray and desloratadine tablets in patients with allergen-induced seasonal allergic rhinitis (SAR). RESEARCH DESIGN AND METHODS: 46 adult patients with a history of SAR were exposed to a controlled grass pollen concentration for 6 h in the Vienna Challenge Chamber (VCC) in each treatment period according to a randomised, double-blind (double-dummy), three-period, three-sequence crossover design (wash-out period of 12 days). Single doses of study medication (one puff nasal spray into each nostril of azelastine, 0.2 mg, or placebo before swallowing one encapsulated tablet of desloratadine, 5 mg) were administered 2 h after the start of the allergen challenge. Results of subjective and objective assessments were recorded throughout the challenge. RESULTS: Efficacy of azelastine nasal spray was significantly superior compared to desloratadine tablets (p = 0.005) and placebo (p < 0.001). Desloratadine was significantly better than placebo (p < 0.001). Decrease both in Major Nasal Symptom Score (MNSS) and in Total Nasal Symptom Score (TNSS) was fastest after azelastine treatment. Improvement of nasal symptom severity was most pronounced after azelastine treatment for all nasal symptoms including nasal congestion. Onset of action was 15 min for azelastine compared to 150 min for desloratadine. Both active preparations were safe and well tolerated. CONCLUSIONS: This study confirms the usefulness of azelastine nasal spray for the symptomatic treatment of seasonal allergic rhinitis. Concerning onset of action in particular, the results favour the topical treatment over systemic therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With the given level of technical and clinical validation, ACCs have been intensively used in clinical drug development to study pharmacological properties of new drugs during phase II trials, such as dose-finding,1039-1041 onset of action,1042-1046 and duration of action.1047-1049”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1046]
Citations
Cites
Ward, A., & Clissold, S. P. (1987) · Drugs · doi:10.2165/00003495-198734010-00003 · Cited by 1,754
Dykewicz, M. S., Fineman, S., Skoner, D. P., Nicklas, R., Lee, R., Blessing-Moore, J., Li, J. T., Bernstein, I. L., Berger, W., Spector, S., et al. (1998) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)63155-9 · Cited by 652
Grossman, J. (1997) · Chest · doi:10.1378/chest.111.2_supplement.11s · Cited by 447
McTavish, D., & Sorkin, E. M. (1989) · Drugs · doi:10.2165/00003495-198938050-00005 · Cited by 124
Horak, F., Stübner, U. P., Zieglmayer, R., & Harris, A. G. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.124657 · Cited by 111
Self-citationCiprandi, G., Pronzato, C., Passalacqua, G., Ricca, V., Grogen, J., Mela, G. S., VARESE, P., Bertolini, C., Bagnasco, M., & Canonica, G. W. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)80196-5 · Cited by 107
Desloratadine: An Update of its Efficacy in the Management of Allergic Disorders
Murdoch, D. R., Goa, K. L., & Keam, S. J. (2003) · Drugs · doi:10.2165/00003495-200363190-00010 · Cited by 74
McNeely, W., & Wiseman, L. R. (1998) · Drugs · doi:10.2165/00003495-199856010-00011 · Cited by 68
Horak, F., Stübner, P., Zieglmayer, R., Kavina, A., De Vos, C., Burtin, B., & Donnelly, F. (2001) · International Archives of Allergy and Immunology · doi:10.1159/000053799 · Cited by 66
Self-citationEnvironmental exposure unit: a system to test anti-allergic treatment
Day, J. H., & Briscoe, M. P. (1999) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)62616-6 · Cited by 53
Research works printed but not linked: 4
- Horak F, 1987, Wien Klin Wochenschr, 99, 509
- Horak F, 2001, d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol, 125, 73
- Baumgarten CR, 1994, J Pharmacol Ther, 3, 43
- Horak F, 2000, Allergy, 55, S279
Cited by
The diagnosis and management of rhinitis: An updated practice parameter
WALLACE, D., DYKEWICZ, M., BERNSTEIN, D., BLESSINGMOORE, J., COX, L., KHAN, D., LANG, D., NICKLAS, R., OPPENHEIMER, J., & PORTNOY, J. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.06.003 · Cited by 1,096
“Azelastine and olopatadine are the only intranasal antihistamines currently available in the United states, are approved for the treatment of seasonal allergic rhinitis, and have been shown to improve congestion, rhinorrhea, sneezing, and nasal pruritus.(334,335) These agents may be considered as a first-line treatmen…”
BackgroundClinical Practice Guideline: Allergic Rhinitis
Seidman, M. D., Gurgel, R. K., Lin, S. Y., Schwartz, S. R., Baroody, F. M., Bonner, J. R., Dawson, D. E., Dykewicz, M. S., Hackell, J. M., Han, J. K., et al. (2015) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599814561600 · Cited by 671
“Intranasal antihistamines also have the advantage of rapid onset of action in the range of 15 to 30 minutes, which is much faster than in the oral route (average onset 150 minutes).(231,237) Numerous studies have compared INS to intranasal antihistamines.”
BackgroundBousquet, J., Schünemann, H. J., Togias, A., Bachert, C., Erhola, M., Hellings, P. W., Klimek, L., Pfaar, O., Wallace, D., Ansotegui, I., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.049 · Cited by 609
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
Metadata
- Authors
- Horak, F., Petra Zieglmayer, U., Zieglmayer, R., Kavina, A., Marschall, K., Munzel, U., & Petzold, U.
- Affiliations
- Allergiezentrum Wien West (AT)
- Hochbahn (Germany) (DE)
- Corresponding author
- Horak, Friedrich
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2005-12
- Volume
- 22
- Issue
- 1
- Pages
- 151-157
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2150163190
- Cited by
- 98
- References
- 14
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 7 · 2019: 13 · 2018: 6 · 2017: 6 · 2016: 6 · 2015: 3 · 2014: 3 · 2013: 5 · 2012: 1
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- desloratadine, allergic rhinitis, onset of action, nasal congestion, nasal symptom score
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Female, Rhinitis, Allergic, Seasonal, Humans, Male, Middle Aged, Phthalazines, Pollen, Tablets, Treatment Outcome, Loratadine, Anti-Allergic Agents, Histamine H1 Antagonists, Non-Sedating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. https://app.cochat.ai/papers/10.1185/030079906x80305
- The paper
- Horak, F., Petra Zieglmayer, U., Zieglmayer, R., Kavina, A., Marschall, K., Munzel, U., & Petzold, U. (2006). Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Current Medical Research and Opinion. https://doi.org/10.1185/030079906x80305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.